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Background: Lumefantrine, an antimalarial molecule has very low and variable bioavailability owing to its
extremely poor solubility in water. It is recommended to be taken with milk to enhance its solubility and
bioavailability. The aim of present study was to develop a Self Nanoemulsifying Delivery system (SNEDs) of
lumefantrine (LF) to achieve rapid and complete dissolution independent of food-fat and surfactant in dissolution
media.
Methods: Solubility of LF in oil, co-solvent/co-surfactant and surfactant solution and emulsification efficiency of
surfactant were analyzed to optimize the LF loaded self nanoemulsifying preconcentrate. Effect of LF-oleic acid
complexation on emulsification, droplet size, zeta potential and dissolution were investigated. Effect of milk
concentration and fat content on saturation solubility and dissolution of LF was investigated. Dissolution of
marketed formulation and LF-SNEDs was carried out in pH 1.2 and pH 6.8 phosphate buffer.
Results: LF exhibited very high solubility in oleic acid owing to complexation between tertiary amine of LF and
carboxyl group of oleic acid (OA). Cremophore EL and medium chain monoglyceride were selected surfactant and
co-surfactant, respectively. Significantly smaller droplet size (37 nm), shift in zeta potential from negative to positive
value, very high drug loading in lipid based system (> 10%), no precipitation after dissolution are the major
distinguish characteristics contributed by LF-OA complex in the SNED system. Saturation solubility and dissolution
study in milk containing media pointed the significant increment in solubility of LF in the presence of milk-food fat.
LF-SNEDs showed > 90% LF release within 30 min in pH 1.2 while marketed tablet showed almost 0% drug release.
Conclusion: Self nanoemulsification promoting ionic complexation between basic drug and oleic acid hold great
promise in enhancing solubility of hydrophobic drugs.Introduction
Poor aqueous solubility of the existing and New Chemical
Entities adversely affects the oral bioavailability. Failure to
mimic in vivo performance compare to in vitro potential,
variable absorption and so the plasma concentration, re-
quirement of higher dose than actually needed for desired
pharmacological activity are some of the major problems
associated with poor solubility of drugs. Further, molecules
having very poor aqueous solubility with poor oil solubility* Correspondence: vaviapr@yahoo.com
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reproduction in any medium, provided the orimpose greater formulation challenges for pharmaceutical
scientists. Self emulsifying drug delivery system is one the
promising strategy to overcome the solubility barrier
of drugs, with commercial products in market e.g.
Cyclosporin A, Ritonavir, Lopinavir, Fenofibrate etc.
Although a versatile approach, it is not suitable for
inherently poor oil soluble molecules e.g. Itraconazole,
Carbamazepine, Lumefantrine etc. [1-3].
Lumefantrine (LF) is a highly lipophilic flourene deriva-
tive and a Biopharmaceutical Classification System (BCS)
Class II drug which is an important agent in the treatment
of falciparum malaria. Plasmodium Falciparum is an
insidious malarial parasite that fatally threatens a major
segment of the Sub-Saharan population in Africa. Thus
far, existing therapies for treatment of this form of malariad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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insufficient bioavailability afforded by drugs of the quinine
class. Lumefantrine is a blood schizonticide, acts by
inhibiting detoxification of haem, this toxic haem and free
radicals induce parasite death [4,5].
Although a very efficacious molecule, its activity is lim-
ited by extremely poor aqueous solubility. Its solubility is
far below the critical solubility requirement and so the
reported bioavailability is 4–11%. Such vast variability in
bioavailability is contributed by the effect of food-fat con-
sumption. Low intrinsic clearance and erratic oral variabil-
ity and therapeutic levels are more reliably achieved by
co-administration with a fatty meal. The oral bioavailabil-
ity of lumefantrine is highly dependent on food and is
consequently poor in acute malaria, showing high degree
of variation in different subjects [6]. Poor solubilization
leads to incomplete absorption and so inadequate plasma
concentrations for antimalarial activity. Due to this
chances of treatment failure are higher, which is again
associated with increased morbidity, transmissibility and
development of resistance. Lumefantrine is an extremely
well-tolerated drug, so it is essential to ensure its max-
imum absorption [6]. Generally milk is recommended to
be taken with lumefantrine but availability of milk and its
fat content might vary region to region and the variation
in antimalarial response to it. This inter-subject variability
may gradually induce resistance to artemisinin-based
combination therapy, thus making it crucial to increase
the dosage regimen. There is only one report on enhance-
ment of dissolution of LF by wet milling technique. How-
ever, Nano milling is very high energy consuming process;
moreover paper states that nanopowder lumefantrine also
requires benzalkonium chloride (BKC) in dissolution
media for solubilization [7]. So far there is no report on
solubility enhancement of LF by Self nanoemulsifying sys-
tem. Self nanoemulsifying systems are very well reported
in literature for enhancement in solubility of lipophilic
drugs. Self emulsifying preconcentrate is made of oil, sur-
factant, co-surfactant and drug. On dispersion in water it
forms < 100 nm sized droplets. Based on oil characteristic
it is directly disseminate to systemic circulation or absorb
via lymphatic pathway. Oil-surfactant-cosurfactant driven
very high solubility, nano-size and permeability results in
significantly rise in bioavailability. The spontaneous forma-
tion of nanosized emulsion droplets in stomach generates
enormously high surface area for drug to diffuse in lumen
and absorb rapidly [3,8].
Poor oil solubility of LF has restricted development of
lipid based system. In view of this inadequacy, the current
study aims at improving the solubility of lumefantrine,
especially to eliminate the co administration of milk or
any other fatty meal. Considering the basic nature of LF,
we have planned to form LF-oleic acid ionic complex and
to prepare self emulsifying system of complex by additionof appropriate surfactant. Such a self emulsifying hydro-
phobic complex enable rapid dissolution of LF, without
need of BKC in dissolution media, hence provide better
correlation to in vivo condition. Till date, there is no
report on preparation of self emulsification system with
drug – oil ionic complex. The main objective of the study
was to develop a self nanoemulsifying delivery system of




Lumefantrine was procured from Mangalam Laboratories
Pvt Ltd (India). The following materials were procured
from gattefosse India and were used as received: Labrafac
CM10 (C 8 -C 10 polyglycolized glycerides), Maisine 35–1
(glyceryl monolinoleate), Lauroglycol FCC (propylene gly-
col laurate), Labrafil 1944 CS (apricot kernel oil polyethyl-
ene glycol [PEG] 6 esters) and Labrafac PG (propylene
glycol caprylate/caprate). Cremophor RH 40 (polyoxyl 40
hydrogenated castor oil), Cremophor EL (polyethoxylated
castor oil and Solutol HS 15 (polyoxyethylene esters of
12-hydroxystearic acid) were obtained from BASF India
Ltd. Gelucire 44/14 (PEG-32 glyceryl laurate) and
50/13 (PEG-32 glyceryl palmistearate) were received
from Colorcon Asia (India). Oleic acid, Tween 80
(polyoxyethylene sorbitan monooleate) and PEG 400
were purchased from Merck (India). Deionized water
was prepared by a Milli-Q purifi cation system from
Millipore (France). Acetonitrile and methanol used in
the present study were of high performance liquid
chromatography (HPLC) grade. All other chemicals
were reagent grade. Empty HPMC capsule shells were
procured from ACG Capsules (Mumbai). Milk of different
fat content was purchased from Aarey dairy (1.5% fat con-
tent) and Gokul dairy (3% fat content) India.
Analytical method
A simple HPLC method was developed for quantitative
analysis of lumefantrine in the formulation. The HPLC
system was equipped with Jasco PU2080 plus pumps with
PDA detector and auto sampler unit. The drug was
analyzed using Hypersil C18 column (250 mm × 4.6 mm,
5 μm) with mobile phase composition Methanol – 0.1%
TFA in water in the ratio of 80:20 v/v, with 1.5 ml/min
flow rate and detector wavelength set to 336 nm.
Methods
Screening of oil
Saturation solubility of Lumefantrine in oil was chosen as
the criteria of selection. The solubility of the drug was
determined in various natural and derived oils. 1 ml of
each of the selected vehicles was added to each cap vial
containing an excess of LF. Mixing of the systems was
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then shaken with a shaker at 37°C for 48 hours. After
reaching equilibrium, each vial was centrifuged at 15,000
rpm for 5 minutes. The solubility of lumefantrine in oil
was then quantified by HPLC method.Screening of surfactant and co-surfactant
Screening of surfactant was done on the basis of (i) Solu-
bility of LF in surfactant solution and (ii) its emulsification
efficiency for LF-oil mixture.
Saturation solubility of the drug was determined in vari-
ous surfactant solution (1% w/v solutions in water) and
co-surfactant. An excess amount of LF was added to 5 ml
of the surfactant solution and co-surfactant/co-solvent.
Samples were placed in a water shaker bath for 48 hrs.
The sample was then centrifuged (15,000) for 10 min
followed by analysis of supernatant by HPLC. Oleic acid
was selected as oil for lumefantrine solubilization. Various
Surfactants, co surfactant and combination thereof were
mixed with oleic acid and LF-oleic acid solution in various
ratios. The co-solvent/co-surfactant were screened on the
basis of emulsification time, droplet size, appearance of
final system and its reports on compatibility with capsule
shell. 500 mg of each mixture (oleic acid-surfactant or
LF-oleic acid-surfactant) was added to 250 ml of water
(37°C) with mild stirring (100 rpm on magnetic stirrer).
The compositions were evaluated for their emulsifying
efficiency for oleic acid and LF-oleic acid mixture. Emulsi-
fication time, appearance and type of emulsion, LF pre-
cipitation and stability for 24 h etc. parameters were
considered to evaluate the emulsification efficiency of
surfactant.
LF-SNEDs (Lumefantrine-Self Nanoemulsifying Delivery
System) was prepared by dissolving LF in oleic acid (min-
imal amount require for LF solubilization). Optimized
mixture of Surfactant and co-surfacatant were added to
LF-oleic acid mixture. Fixed weight of Lumefantrine: Oleic
acid (100 mg:325 mg) was mixed with various ratios of
Cremophore EL and different co-solvents and co-
surfactants. Droplet size and emulsification time was
evaluated in order to optimize the quantity of surfactant
and co solvent/co surfactant. The prepared LF-SNEDs
preconcentrate was filled into HPMC capsules.Table 1 Preparation of dissolution media
Dissolution media Deionised water Milk
pH 1.2 buffer USP (HCl) 900 0
800 100
700 200
pH 6.8 phosphate buffer USP 900 0
800 100
700 200Droplet size and zeta potential measurement
One hundred microliters of each LF-SNEDs preconcentrate
was added to 100 ml of miliQ water, and gently mixed
using a glass rod. The resultant emulsion was analyzed
for droplet size (z average diameter) by Dynamic
Light Scattering (DLS) using Malvern Zetasizer, USA.
The same procedure of dilution used to measure zeta
potential by laser dopper microelectrophoresis using
same instrument.Saturation solubility of lumefantrine in milk containing
media
Eventhough LF is recommended to be taken with milk,
there has been no literature report hitherto on the effect of
milk on the solubility of lumefantrine. In an attempt to
check the solubility of lumefantrine in milk containing
varying amounts of fat, the following two types of milk
were chosen: milk containing 1.5% fat (a) and 3.1% fat (b).
Milk of types a and b were added to different test tubes
containing water at pH 1.2 buffer USP (Hydrochloric acid)
and pH 6.8 phosphate buffer USP at a concentration of
20% v/v under the assumption that an average person con-
sumes 200 ml of milk in a day. Excess amount of drug was
added to each test tube and it was kept in a water shaker
bath for 24 hours. Thereafter solutions were filtered
through 0.45 μm filter to remove the insoluble drugs.
Filtrate was diluted suitably distilled water followed by
extracted by chloroform. After evaporating chloroform
and reconstituting with mobile phase LF was quantified
using HPLC. The saturation solubility of lumefantrine
with increasing concentrations of milk at different pH
was calculated.In vitro dissolution study
Dissolution of Marketed Formulation was carried out in
surfactant free dissolution media with and without milk.
Instead of using Fed state dissolution media, a real time
method to account for variability in ingested food was
used by adding 100 mL and 200 mL of low-fat milk (a) to
each dissolution flask respectively. The composition of
dissolution media for marketed formulation is mentioned
in Table 1. Dissolution of marketed preparation was
carried out using USP XXIII apparatus I at 37 ± 0.50°C
with a rotating speed of 100 rpm. Samples were taken at
every 15 min from each of the flasks and the percentage
cumulative release was calculated.
LF-SNEDs preconcentrate was filled in size ‘0’ HPMC
capsules. Dissolution Test of LF-SNEDs was carried out in
similar dissolution media using sinker. The composition
of milk containing dissolution media showed in Table 1.
Table 3 Saturation solubility of LF in surfactant solution
Surfactant solution (1%) Solubility (μg/ml) (Mean± SD) (n=3)
Acconon MC8 0.26 ± 0.14
Sodium Deoxytaurocholate 1.33 ± 0.09
Sodium taurocholate 1.42 ± 0.14
Tween 20 9.18 ± 0.13
SLS 10.75 ± 0.28
Lutrol 13.01 ± 0.15
Acconon S 35 13.05 ± 0.17
Gelusire 15.18 ± 0.17
Solutol HS 15 22.49 ± 0.21
TPGS 27.18 ± 0.28
Cremophore EL 44.52 ± 0.29
Cremophore RH40 46.94 ± 0.25
Tween 80 101.63 ± 0.37
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Screening of oil
The core part of SNEDs is composed of oil, in which
drug is solubilized. Hence, it is very much essential to
choose the oil having higher solubility for drug. Various
types of oil have been screened including fatty acids,
medium chain mono/di/tri glycerides, propylene mono/
di glycerides and long chain triglycerides. Castor oil and
GMO showed minimal solubility of LF while Medium
chain triglycerides, Isopropyl myristate, rice germ oil etc.
showed moderate solubility of LF (Table 2). The higher
solubility in rice germ oil may be attributed to its high
oleic acid content and γ-orizynol [9]. Oleic acid showed
significantly higher solubility of lumefantrine – 157 mg
of LF/gm of oleic acid. Such a higher solubility is not
merely expected form hydrophobic interaction between
LF and oleic acid. There must be ionic interaction attri-
butes to this solubility enhancement.
Screening of surfactant
Selection of suitable surfactant is very crucial part for self
emulsifying system especially when a fine translucent
nanosized emulsion is required. Surfactant was selected
on the basis of two criterions: saturation solubility of
lumefantrine in 1% w/v surfactant solution (Table 3) and
its emulsification efficiency for LF-oleic acid (Table 4).Table 2 Saturation solubilities of drug in vehicles
Vehicle Solubility (mg/gm) ± SD (n=3)
Oil
Castor Oil 5.91± 0.21
Glyceryl Monooleate 7.79 ± 0.29
Sunflower oil 10.57 ± 0.42
Olive oil 11.67 ± 0.37
Acconon CO7 13.22 ± 0.24
Groundnut Oil 14.16 ± 0.43
Corn Oil 19.34 ± 0.61
Captex 300 29.62 ± 0.72
Till oil 33.40 ± 0.8
Isopropyl Myristate 40.85 ± 0.74
Rice germ Oil 59.92 ± 1.19
Oleic Acid 157.20 ± 1.38
Co-surfactant
Capmul MCM C8 14.99 ± 0.48
Capmul PG8 18.13 ± 0.49
Co-solvent
Propylene Glycol 0.432 ± 0.11
Ethanol 2.831 ± 0.29
PEG 400 2.852 ± 0.18
Transcutol P 19.267 ± 0.58
Benzyl alcohol 78.024 ± 1.41Surfactants of chemical diversity – ionic (cholate, SLS)
and non ionic (PEG fatty acid esters, PEO-PPO-PEO block
co polymers, PEG vitamin E esters etc.) have been
screened for solubility of lumefantrine. LF was almost
negligible soluble in PEG-medium chain fatty acid ester
(Acconon MC8), marginal solubility in ionic surfactant,
with highest solubility in Tween 80 (100 ppm). Tween 80
was selected as the surfactant in trials with different
co-surfactants to assess the ability of the co-surfactants to
improve the clarity of the system. However, Tween 80
does not show good emulsification as the final system
remained hazy. Eventhough LF exhibited highest solubility
in Tween 80, it was rejected bacause its poor emulsifica-
tion property for LF-oleic acid (Table 4).
LF-oleic acid-cremophore EL preconcentrate was self
nanoemulsify to 50–100 nm sized droplet depending on
the amount of cremophore EL (Table 5). However, in all
the bathces have shown longer self emulsification time
(~ 7 min) on additon into water (Table 6). Reduction in
self emulsification time is necessary to release LF
immidiately. In order to reduce the emulsification time,
addition of co-solvent or co-surfactant facilitating the
emulsification process was added. Various co-solvent/
co-surfactant were screened for this purpose. Solubility
of LF in Co co-solvent/co-surfactant was not considered
as an important criteria for its selection because of very
poor solubility of LF in Medium chain monoglycerides,
ethanol, PEG and transcutol P. solubiliy of LF was found
to be higher in benzyle alcohol compare to other
solvents but was rejected in formualtion due to its lower
acceptibilty limit and volatile nature.
The emulsification time and appearance of the formu-
lation with different co-surfactants with Cremophore
EL were shown in Table 6. Further, droplet size and
polydispersity index of various batches of LF-oleic acid
mixture with in different ratio of cremophore EL with
Table 4 Emulsification behavior of Oil and Surfactant mixture
Composition Surfactant Observation Emulsification
Oleic Acid Gelusire 44/14, Tween 80, Solutol HS 15, TPGS, Lutrol F68 Turbid Poor
LF-Oleic Acid Gelusire 44/14, Tween 80, Solutol HS 15, TPGS Turbid Poor
Oleic Acid Cremophor RH40 Translucent milky solution Satisfactory
LF-Oleic acid Cremophor RH40 Translucent Good
Oleic Acid Cremophore EL Translucent Good
LF-Oleic Acid Cremophore EL Clear and translucent Excellent
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Table 5.
It was found that a oil:surfactant ratio of 1:1.2 yielded
the smallest droplet size and a clear translucent system,
however, in an attempt to reduce the amount of surfactant
in the system the droplet size was compromised slightly
and the surfactant concentration was reduced. Thus, a
system with an oil:surfactant ratio of 1:1 was chosen. Al-
though transcutol acts as an effective co-solvent in terms
of emulsification capacity, it slows down the emulsification
time for the system. PEG-400, inspite of being a good can-
didate for a co-solvent was not chosen due to its hygro-
scopic tendencies in soft and hard gelatin capsules.
Ethanol was not considered as a co-solvent in the final for-
mulation due to its tendency to diffuse out of the shell
and it threatens the integrity of the capsule. Capmul
MCM-C8, a medium chain monoglyceride was selected as
co-surfactant in finally optimized system (LF-SNEDs)
since it has given minimal droplet size of 37 nm (Table 5)
with comparatively rapid emulification (Table 6). More-
over there is no report on its any chemical or physical
interaction with capsule shell.
Zeta potential
In this study, to account for the electrostatic effects of the
drug-lipid interaction, the zeta potential values of self-Table 5 Particle size analysis of various formulations




F4 Transcutol P (25) 25
F5 Transcutol P (25) 32
F6 Transcutol P (25) 40
F7 Capmul MCM (25) 25
LF-SNEDs Capmul MCM (25) 32
F9 Capmul MCM (25) 40
F10 Capmul MCM (50) 32
F11 PEG 400 (25) 32
F12 Ethanol (25) 32
F13 Capmul PG8 32emulsified formulation were measured at the same drug
to lipid ratios as optimized in the above experiments. Zeta
potential of SNEDs with and without drug was evaluated
to understand effect of LF-oleic acid complex on surface
charge. The Zeta Potential of oleic acid self emulsifying
system was found to be – 6.73 mv while LF loaded SNEDs
exhibited + 4.4 mv zeta potential. The graphical presenta-
tion of droplet size, zeta potential and possible orientation
of surfactant in LF-SNEDs showed in Figure 1. This indi-
cates the blank formulation has negative zeta potential
while addition of drug lead to shift in zeta potential to
positive side. The results are in agreement with a study by
Nagarsenker et al., suggesting that addition of a basic drug
lead to shift in zeta potential from negative to positive
[10]. The final composition of LF-SNEDs is mentioned
in Table 7.
Saturation solubility of lumefantrine in milk containing
media
The saturation solubility of lumefantrine in milk containing
media at gastric and intestinal pH was analyzed
(Figure 2). Saturation solubility of LF was found to be
significantly influenced by pH and presence milk. How-
ever, in absence of milk LF showed almost negligible
solubility in both pH 1.2 and pH 6.8 buffers. As
expected LF has higher solubility at lower pH due to itsemophore EL (mg) Particle size (nm) PDI
0 94.51 ± 7.67 0.329
5 65.43 ± 5.49 0.229
0 48.4 ± 5.3 0.25
0 72.25 ± 6.7 0.235
5 60.5 ± 5.3 0.21
0 50.25 ± 6.2 0.227
0 80.39 ± 8.7 0.254
5 37.96 ± 4.1 0.184
0 53.78 ± 4.81 0.211
5 39.49 ± 4.4 0.119
5 52.98 ± 4.7 0.123
5 41.59 ± 3.5 0.139
5 51.71 ± 3.9 0.122
Table 6 Effect of different co-surfactants on emulsification time
Co-surfactant Emulsification time (min) Observations
Transcutol P 6.17 Long time to disperse but final system is clear
PEG-400 4.30 Clear system
Capmul PG8 4.70 Translucent nanoemulsion
Capmul MCM-C8 3.16 Translucent nanoemulsion
Without any co-solvent 7.0 Highly viscous clumps take a long time to disperse
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crease the fat content of milk, with maximum solubility of
24 ppm was observed in media containing 20% v/v high
fat milk at pH 1.2 (Figure 2). Further increase in fat con-
tent or milk concentration is expected to proportionally
enhance the solubility of LF.
Dissolution profile of marketed formulation in milk
containing media
Dissolution profile clearly states that release of LF is
highly depend on concenration of milk in dissolution
media (Figure 3). The results of dissolution sutdies are
complemetaty to saturation solubility study of LF in
milk containing media. The dissolution medium with-
out milk showed negligible release and hence it can be
predicted that without fat containig food suppliment,
bioavailbility and therefore therapeutic response may be
very poor. Milk containing dissolution media showed
marginal improvement in dissolution of LF. Dissolution
of LF is higher at pH 1.2 media compare to pH 6.8, irre-
spective of milk content. Higher dissolution at pH 1.2 is
due to its higher solubility at lower pH. The cumulativeFigure 1 Graphical presentation of SNED and LF-SNEDs.release increases to maximum 12% upon the ingestion
of 200 ml of milk in gastric pH.
Dissolution test of lumefantrine self nanoemulsifying
system
Comparable dissoluiton profile of marketed formulation
and LF-SNEDs at pH 1.2 and pH 6.8 shown in Figure 4.
Marketed formulation showed almost negligible release
over the period of 60 min, which is by virtue of extemley
poor solubility of lumefantrine in aqeous media. LF-
SNEDs exhibited significantly enhancement in dissolution
compare to marketed preparation. At pH 1.2, more than
90% of LF was found to release within 30 min account
of rapid formation of nanoemulasion in contact with
aqeuous medium.
Discussion
Oleic acid showed highest solubilizaion capacity of LF
owing to complexation between tertiary amine of LF and
oleic acid. Complexation of LF and oleic acid was indir-
ectly confirmed by addition of stronger base than
lumefantrine. It was assumed that addition of stronger
Table 7 Composition of LF-SNEDs
Lumefantrine 100 mg
Oleic acid 325 mg
Cremophore EL 325 mg
Capmul MCM 25 mg
Total 775 mg
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plexation of amine group of LF with carboxylic acid of
oleic acid. The reported pKa value of halofantrine (a simi-
lar class of drug) is in the range of 8.2 [11]. So on the basis
of structural similarity we assumed that lumefantrine has
similar pKa. The pKa of Triethylamine (TEA) is 10.5,
which depicts that it is stronger base than lumefantrine.
LF was found to be insoluble in oleic acid in the presence
of TEA. On this basis it was confirmed that ionic com-
plexation is responsible for significant higher solubility of
LF in oleic acid.
Further experimentation on self emulsification property
of oleic acid and LF-oleic acid suggested the proof of
concept of ionic complexation between LF and oleic acid
promote self emulsification (see graphical abstract). It was
discovered that a system consisting of only oleic acid (no
drug), surfactant and co-solvent is self nanoemulsifying to
120 ± 12 nm while system containing LF-oleic acid,
surfactant and consurfactant easily emulsify to nano size
translucent dispersion of 37.96 ± 4.1 nm. Addition of LF
showed 4 times reduction in droplet size. It means that
LF-oleic acid complex is itself promoting the self emulsifi-
cation, which is otherwise difficult to emulsify oleic acid.
We can attribute this to the fact that oleic acid interacts
with the amine drug and forms a hydrophobic ion-pairing
complex with its carboxylic group. Thus, the functionalFigure 2 Saturation solubility of lumefantrine in different types of migroup of oleic acid which might br interfering in self
emulsification, on complexation with drug to it promote
the self-emulsifying property. Based on the above results,
Oleic acid was selected as the oil. The interaction was
reflected in zeta potential study. Shift in Zeta potential of
plain oleic acid nanoemulsion – 6.73 mv to + 4.4 mv with
LF-oleic acid nanoemulsion also support the ionic inter-
action between amine of LF and carboxylic acid group of
oleic acid. The blank formulation has a negative charge
due to the predominance of the anionic oleic acid. The
negative charge of blank system is due to presence of
carboxylic acid group on surface. Very marginal negative
potential of the system is due to poor ionization of oleic
acid (pKa – 9.85). Moreover, dense network of PEG of
cremophore EL on surface mask zeta potential of the
ionized species on surface. Zeta potential of LF-SNEDs
was found to be slightly positive, clearly indicating the
ionic interaction of LF-oleic acid. The positive charge, in
LF-SNEDs can be attributed to masking of anionic charge
of oleic acid by complexation with LF and surface orienta-
tion of amine group of LF in nanoglobules. This inter-
action results in significantly higher solubility of LF in
oleic acid, further LF-oleic acid complex is expected to be
more soluble in oleic acid than lumefantrine itself.
Tween and cremphore both are PEG fatty acid esters
but their chemical structures have vast diffence. Crem-
phore surfactants are more bulky and having higher
molecular weight compare to Tween surfactants. Tween
80 has single chian of oleic acid as lipophilic part while
cremophore surfactants have three fatty acid chain
attahced to PEG-glycerol. This bulkier lipophilic part of
cremophore may contributed to better emulsification
property of cremophore EL and cremophore RH 40.
Hence, further formulations were tested with Cremophorelk at different pH.
Figure 3 Dissolution profile of marketed formulation in milk containing dissolution media.
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fatty acid e.g. oleic acid is difficult to emulsify in
comparision to its glyceryl esters. Though Cremophore
RH 40 showed a slightly better solubilising capacity, it was
dismissed in favour of Cremophore EL as the latter
portrayed a clearer and more transparent emulsion on
redispersion. Also, Cremophor RH40 (polyoxyl 40 hydro-
genated castor oil) appeared to be less readily digested
than Cremophor EL (polyoxyl 35 castor oil). An explan-
ation for differences in the digestability of the structurally
similar Cremophor surfactants is not very clear in litera-
ture but may reflect differences in the reactivity of the sat-
urated (hydrogenated) castor oil glyceride backbone in
Cremophor RH40 leading to the generation of slightly
different reaction products with polyethylene oxide, whenFigure 4 Dissolution profile of marketed formulation and LF-SNEDs.compared with Cremophor EL (which is generated by
polyethoxylation of unsaturated castor oil) [12]. Alterna-
tively the slightly larger polyethylene oxide content of
Cremophor RH 40 may have more effectively masked the
approach and binding of pancreatic enzymes (and there-
fore hydrolysis) when compared with Cremophor EL.
Cremophore EL has an IIG limit of 599 mg making it a
feasible and non-toxic component in the system.
Self-emulsification of oil-surfacatant preconcentrate
proceeds through formation of Liquid Crystalline phase
(LC) at oil–water interface. The rate and extent of water
penetration into LC phase determines the rate of emul-
sification. Rapidity of self emulsification is governed by
weakness and viscosity of intermediate LC [13,14].
Medium chain monoglyceride (MCM) has ability to
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It was observed that increasing concentrations of fat
in milk brought about an increase in saturation solubil-
ity of lumefantrine whereas no solubility was observed
at the gastric and intestinal pH in the absence of milk.
Triglycerides are the major component of milk fat.
These medium to long chain triglycerides of milk contrib-
uting to marginal solubility of lumefantrine in milk.
Higher the fat content of milk, higher will be the solubility
of LF in it.
This indicates the extreme necessity of fat containing
diet for its solublilization and therefore absoption. Possi-
bility of failure in therapetic response can not be denied
with such a poorly soluble drug as discussed in introduc-
tion part.
Increase in solubility with increase in milk content is
prime reason for enhacement in bioavailability of LF when
given with milk. The results are in agreement with a bio-
availability study carried out on healthy human volunteer
to evaluate the effect of food/fat on bioavailability of LF.
Bindschedle et al. have reported 16 fold enhancement in
bioavailability in the presence of food [15]. Ashley et al.
have reported 90% of maximum AUC was achieved with
36 ml of soya milk [6]. Ensuring that volunteer receives
milk or fat with given medicine is feasible under study
conditions but difficult to guarantee during routine treat-
ment in malaria patients. However, the availability of milk,
composition of fat and the amount of milk consumed var-
ies from person to person and thus there is no conclusive
prediction of the bioavailability in the LF.
LF-oleic acid ionic hydrophobic complex emulsify to
nanosize by cremophore EL, generating an enormously
high surface area. Accroding to noyes-whitney equation
reduction in droplet size lead to significant enhancement
in dissolution while Prandlt equation suggests the signifi-
cant reduction in diffusion layer thickness with nanosizing
of particle [16].
One more important thing to take into consideration
is dissolution media does not contain any surfactant.
Generally, in dissolutin studies of hydrophobic drug,
surfactant is added to maintain sink condition and to
prevent precipitaion of drug-in dissolution media. USP
recommonds use of 1% w/v Benzalkonium chloride
(BKC) in dissoultion media. The saturation solubilty of
LF in 0.1 M HCl with 1% w/v BKC is 119 ± 3 ppm, suffi-
cient to solubilize 120 mg of LF in dissolution media
[16]. The most important advantage of LF-SNEDs sys-
tem is complete dissolution of LF without use of such
surfactant in dissoltion media. Both the dissolution
media pH 1.2 and pH 6.8, do not contain BKC or other
surfactant, still LF-SNEDs capable enough to solubilize
drug without precipiatation. Amount of cremophore EL
in dosage form is just 325 mg, leading to 0.36% w/v in900 ml of dissolution media. This concentration is much
below to maitain sink condition for LF in dissolution
media (Table 3). Hence, we can predict that LF remains
in solubilized state in dissolution media because of its
comlexation with oleic acid. The complex formation
promote the faster self emulsification and dissolution
and further inhibit the precipitaion of drug once solubi-
lized. In phosphate buffer 6.8, slow dissolution of capsule
shell resulted in 10 min lag period for solubilitzation.
After opening of capsule dissolution profile is similar
to that of pH 1.2.
Conclusion
Hydrophobic ionic complexation based self nanoemulsifying
delivery system of LF showed remarkabley higher dissol-
ution profile, eliminating the requirement of food/fat for
LF solubilization. Lumefantrine has very high solubility in
oleic acid due to complexation between tertiary amine of
LF and oleic acid. Higher the solubiilty of drug in oil,
higher the drug loading capacity of formulation. For drug
having higher dose, ionic complexation with oleic acid
would be effective strategy to enhance solibilty by self
nanoemulisfying formulation. Selection of an ideal surfac-
tant and co-surfactant is very much essential to emulsify
the complex to nano sized globule within short period of
time. Sponteneous formation of nanoemulsion lead to
rapid dissolution of a hydrophobic drug, which may offer
food/fat independent bioavailability. Ionic complexation
with self emulsifying delivery offer an easy, cost effective
and industry feasible approach for solubilization of basic
hydrophobic drugs.
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